{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:39:23Z","timestamp":1780695563746,"version":"3.54.1"},"reference-count":26,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Hypersensitivity reactions, including anaphylaxis, have been increasingly reported with quinolones.\n                    <jats:bold>Objective:<\/jats:bold>\n                    To characterize the association of different quinolones with anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)\n data base.\n                    <jats:bold>Methods:<\/jats:bold>\n                    We searched the FAERS data base for anaphylactic reaction reports (between 2015 and 2024) associated with the three commonly used fluoroquinolones in the United States, viz., levofloxacin, ciprofloxacin, and moxifloxacin. The reporting odds ratio (ROR)\n was used to assess disproportional reports of anaphylaxis among the individual fluoroquinolones and between the fluoroquinolones and all medications within the data base.\n                    <jats:bold>Results:<\/jats:bold>\n                    We identified 941 anaphylaxis reports (ciprofloxacin, 390; levofloxacin, 299; and moxifloxacin,\n 252) of 89,351 adverse reactions reported for all fluoroquinolones between 2015 and 2024. There were disproportionally higher reports of anaphylaxis among fluoroquinolones compared with all medications within the data base (ROR 4.56 [95% confidence interval {CI}, 4.28-4.87]) but lower relative\n to that of amoxicillin (ROR 0.19 [95% CI, 0.17-0.20]). Within the fluoroquinolones, moxifloxacin was associated with the highest disproportionality signal for anaphylaxis relative to all other medications (ROR 8.65 [95% CI, 7.63-9.80]) and relative to all fluoroquinolones (ROR 1.90 [95% CI,\n 1.65-2.18]), whereas levofloxacin was associated with a disproportionally lower signal when compared with all other fluoroquinolones (ROR 0.77 [95% CI, 0.67-0.88]). The disproportionally higher anaphylaxis report associated with moxifloxacin was especially pronounced among women (ROR 2.11\n [95% CI, 1.78-2.49]) and elderly individuals (ROR 2.74 [95% CI, 2.15-3.48]).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Moxifloxacin is associated with relatively higher anaphylaxis reports when compared with all other quinolones, especially among female and elderly individuals.\n                  <\/jats:p>","DOI":"10.2500\/aap.2025.46.250078","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T04:32:17Z","timestamp":1761712337000},"page":"484-488","source":"Crossref","is-referenced-by-count":2,"title":["Anaphylaxis related to fluoroquinolones: A disproportionality analysis of the FDA Adverse Event Reporting System data base"],"prefix":"10.2500","volume":"46","author":[{"given":"Tyler","family":"Miluski","sequence":"first","affiliation":[{"name":"From the Section of Allergy, Asthma, and Immunology, Penn State College of Medicine, Hershey, Pennsylvania and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharosha","family":"Bhattarai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Penn State College of Medicine, 500 University Drive, PO Box 850, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Al-Shaikhly","sequence":"additional","affiliation":[{"name":"From the Section of Allergy, Asthma, and Immunology, Penn State College of Medicine, Hershey, Pennsylvania and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/IDR.S401663","article-title":"Quinolone Antibiotics: Resistance and Therapy","volume":"16","author":"Tang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B2","doi-asserted-by":"crossref","first-page":"ofac106","DOI":"10.1093\/ofid\/ofac106","article-title":"Immediate hypersensitivity to fluoroquinolones: a cohort assessing cross-reactivity","volume":"9","author":"Azimi","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaip.2018.06.010","article-title":"Drug-induced anaphylaxis documented in electronic health records","volume":"7","author":"Dhopeshwarkar","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","first-page":"363","article-title":"Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients","volume":"22","author":"Do\u00f1a","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s11096-018-0613-0","article-title":"Prevalence and characteristics of hospital inpatients with reported fluoroquinolone allergy","volume":"40","author":"Wall","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"B6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/cea.12099","article-title":"Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved","volume":"43","author":"Blanca-L\u00f3pez","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jaip.2024.03.013","article-title":"Unraveling cephalosporin-associated anaphylaxis: a comprehensive analysis using FDA Adverse Event Reporting System data","volume":"12","author":"Shah","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.jaip.2024.05.042","article-title":"Pediatric drug-induced anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)","volume":"12","author":"Brameli","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B10","doi-asserted-by":"crossref","first-page":"e0015121","DOI":"10.1128\/AAC.00151-21","article-title":"Outpatient fluoroquinolone prescription fills in the United States, 2014 to 2020: assessing the impact of Food and Drug Administration safety warnings","volume":"65","author":"Buehrle","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B12"},{"key":"B13"},{"key":"B14","article-title":"ClinCalc DrugStats Database, version 2024.08.","author":"Kane"},{"key":"B15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/all.12168","article-title":"Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010","volume":"68","author":"Renaudin","year":"2013","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/pds.5018","article-title":"Outpatient fluoroquinolone prescribing patterns before and after US FDA boxed warning","volume":"29","author":"Bratsman","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2165\/00002018-200629110-00008","article-title":"Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use","volume":"29","author":"Sachs","year":"2006","journal-title":"Drug Saf"},{"key":"B18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1398-9995.2010.02460.x","article-title":"In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones","volume":"66","author":"Aranda","year":"2011","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaip.2013.08.012","article-title":"Retrospective study of drug-induced anaphylaxis treated in the emergency department or hospital: patient characteristics, management, and 1-year follow-up","volume":"2","author":"Banerji","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaip.2018.11.023","article-title":"Drug hypersensitivity reactions documented in electronic health records within a large health system","volume":"7","author":"Wong","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaip.2015.05.012","article-title":"Drug-induced anaphylaxis in Latin American countries","volume":"3","author":"Jares","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13223-018-0289-y","article-title":"Drug allergy","volume":"14","author":"Warrington","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pds.3499","article-title":"US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions","volume":"22","author":"Jones","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B26","first-page":"607","article-title":"Allergy to quinolones: low cross-reactivity to levofloxacin","volume":"20","author":"Lobera","year":"2010","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000006\/art00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:22:49Z","timestamp":1761974569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,1]]}},"alternative-id":["1088-5412(20251101)46:6L.484;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250078","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}